Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
Status:
Unknown status
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
In order to further clarify the interaction of PPIs with clopidogrel anti - platelet effect ,
the investigators designed a clinical randomized controlled trials of omeprazole and
pantoprazole antiplatelet effect of clopidogrel .In this experiment , the investigators have
taken a randomized NSTE-ACS hospitalized patients met the inclusion criteria were randomly
divided into omeprazole and pantoprazole groups . On the day of admission , all patients
taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of
clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d ,
pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission (
before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each
taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet
aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical
adverse events ( including death , myocardial infarction , and any revascularization , stent
thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding
events) . To assess the impact of PPIs on clopidogrel antiplatelet effect by observing 1 year
follow-up results , and further explore the optimal combination of dual anti-platelet and
joint PPIs course of treatment , appropriate dosage and the best time to provide reasonable
for clinical programs to create a personalized treatment system , improve the patient's
quality of life .